Abstract

While most inhibitors of histone deacetylases (HDACs) are hydroxamic acid derivatives, several nonhydroxamates have recently been developed as inhibitors and attracted quite a deal of attention. In this review, we present the rational design, inhibitory effect and antiproliferative activity of non-hydroxamate HDAC inhibitors.

Keywords: Histone deacetylase, inhibitor, hydroxamic acid, non-hydroxamate, zinc enzyme, rational drug design, anticancer agent